Top Stories
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
On July 2, 2024, Eisai Co., Ltd., a leading global pharmaceutical company, declared a significant shift ...
News and insights